MCID: SLV026
MIFTS: 59

Salivary Gland Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Salivary Gland Carcinoma

MalaCards integrated aliases for Salivary Gland Carcinoma:

Name: Salivary Gland Carcinoma 12 15
Salivary Gland Cancer 12 36 54 42 15
Malignant Neoplasm of Salivary Gland 12 70
Salivary Gland Neoplasms 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050904 DOID:8850
KEGG 36 H01508
ICD9CM 34 142.8
SNOMED-CT 67 187648003
ICD10 32 C08
UMLS 70 C0036095 C0153362 C0220636

Summaries for Salivary Gland Carcinoma

KEGG : 36 Salivary gland carcinomas are rare tumours representing about 0.5% of all malignancies and less than 5 % of all head and neck cancers. These are a heterogeneous group of tumors that include 24 histologically distinct tumor types. Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor in adults and children. The most common genetic alteration in MECs is a unique translocation t(11;19)(q21;p13) producing the MECT1-MAML2 fusion protein. This fusion transcript can activate transcription of targets in the Notch pathway. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) overexpression is present in a minority of MECs and is associated with higher rate of metastasis and worse overall survival. Recent studies have evaluated the epidermal growth factor receptor family including EGFR and HER2 as potential therapeutic targets.

MalaCards based summary : Salivary Gland Carcinoma, also known as salivary gland cancer, is related to mucoepidermoid carcinoma and mammary analogue secretory carcinoma, and has symptoms including snoring and halitosis. An important gene associated with Salivary Gland Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Notch signaling pathway and ERK Signaling. The drugs Iodine and Pilocarpine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

MedlinePlus : 42 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

Related Diseases for Salivary Gland Carcinoma

Diseases in the Salivary Gland Carcinoma family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 32.2 TP63 SERPINA3 MAML2 EGFR CRTC1 CDKN2A
2 mammary analogue secretory carcinoma 32.1 ETV6 EGFR
3 adenoid cystic carcinoma 31.1 TP63 SERPINA3 MDM2 KIT EGFR CYLD
4 pleomorphic adenoma 30.9 TP63 MDM2 MAML2 CRTC1 CDKN2A
5 pleomorphic adenoma carcinoma 30.6 MAML2 CRTC1
6 oral cancer 30.6 MDM2 EGFR CDKN2A
7 adenocarcinoma 30.5 MET MDM2 KIT HGF EGFR CDKN2A
8 small cell carcinoma 30.5 KIT EGFR CDKN2A
9 skin carcinoma 30.5 SOX2 MDM2 KIT H2AC18 EGFR CYLD
10 breast secretory carcinoma 30.5 SERPINA3 ETV6
11 lung cancer susceptibility 3 30.4 MET HGF H2AC18 EGFR CDKN2A
12 basal cell carcinoma 30.1 TP63 SOX2 MDM2 KIT EGFR CYLD
13 breast cancer 29.5 TP63 SPHK1 SOX2 SERPINA3 MET MDM2
14 salivary gland cancer, adult 11.7
15 salivary gland mucinous adenocarcinoma 11.2
16 sublingual gland cancer 11.1
17 chronic erosive gastritis 10.6 MET HGF
18 mediastinum liposarcoma 10.5 MDM2 CDKN2A
19 doxorubicin induced cardiomyopathy 10.5 MET HGF EGFR
20 malignant peritoneal mesothelioma 10.5 EGFR CDKN2A
21 cervical adenoid cystic carcinoma 10.5 KIT CDKN2A
22 gastric liposarcoma 10.5 MDM2 KIT
23 esophagus verrucous carcinoma 10.5 MDM2 EGFR CDKN2A
24 verrucous carcinoma 10.5 MDM2 EGFR CDKN2A
25 carcinosarcoma 10.5 KIT EGFR CDKN2A
26 hypopharynx cancer 10.5 MET EGFR CDKN2A
27 acral lentiginous melanoma 10.5 MET KIT CDKN2A
28 laryngeal small cell carcinoma 10.5 KIT CDKN2A
29 vulvar disease 10.5 KIT EGFR CDKN2A
30 maxillary sinus benign neoplasm 10.5 KIT CDKN2A
31 synchronous bilateral breast carcinoma 10.5 KIT EGFR BRCA1
32 retroperitoneum carcinoma 10.5 MDM2 KIT CDKN2A
33 gliomatosis cerebri 10.5 MDM2 EGFR CDKN2A
34 peritoneal mesothelioma 10.5 MET EGFR CDKN2A
35 papillary squamous carcinoma 10.5 EGFR CDKN2A
36 inflammatory liposarcoma 10.5 MDM2 CDKN2A
37 lip and oral cavity cancer 10.5 KIT EGFR CDKN2A
38 deafness, autosomal recessive 97 10.5 SERPINA3 MET HGF
39 lacrimal gland mucoepidermoid carcinoma 10.5 MAML2 CRTC1
40 keratinizing squamous cell carcinoma 10.5 MAML2 EGFR CDKN2A
41 warthin tumor 10.5 MAML2 CRTC1
42 papillary thyroid microcarcinoma 10.5 TP63 MET HGF
43 breast malignant phyllodes tumor 10.5 SERPINA3 KIT EGFR
44 pancreas sarcoma 10.5 SERPINA3 MDM2 CDKN2A
45 lung benign neoplasm 10.5 MET EGFR CDKN2A
46 embryonal sarcoma 10.5 SERPINA3 MDM2 KIT
47 mucinous adenocarcinoma 10.5 KIT EGFR CDKN2A
48 undifferentiated embryonal sarcoma of the liver 10.5 SERPINA3 MDM2
49 tenosynovial giant cell tumor 10.5 SERPINA3 KIT CDKN2A
50 heart cancer 10.5 SERPINA3 MDM2 KIT

Graphical network of the top 20 diseases related to Salivary Gland Carcinoma:



Diseases related to Salivary Gland Carcinoma

Symptoms & Phenotypes for Salivary Gland Carcinoma

UMLS symptoms related to Salivary Gland Carcinoma:


snoring; halitosis

GenomeRNAi Phenotypes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.6 EGFR
2 Decreased viability GR00055-A-2 9.6 EGFR
3 Decreased viability GR00221-A-1 9.6 CDKN2A CYLD EGFR HGF KIT SOX2
4 Decreased viability GR00221-A-2 9.6 CYLD HGF
5 Decreased viability GR00221-A-3 9.6 CDKN2A
6 Decreased viability GR00221-A-4 9.6 CDKN2A EGFR HGF SOX2
7 Decreased viability GR00249-S 9.6 CYLD
8 Decreased viability GR00301-A 9.6 CYLD KIT
9 Decreased viability GR00402-S-2 9.6 CYLD

MGI Mouse Phenotypes related to Salivary Gland Carcinoma:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 ACTN4 BRCA1 CDKN2A EGFR ETV6 HGF
2 cellular MP:0005384 10.46 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
3 endocrine/exocrine gland MP:0005379 10.46 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
4 growth/size/body region MP:0005378 10.45 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
5 homeostasis/metabolism MP:0005376 10.43 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
6 immune system MP:0005387 10.42 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
7 behavior/neurological MP:0005386 10.4 BRCA1 CDKN2A CRTC1 CYLD HGF ISL1
8 embryo MP:0005380 10.4 ACTN4 BRCA1 CDKN2A EGFR ETV6 HGF
9 digestive/alimentary MP:0005381 10.38 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
10 hematopoietic system MP:0005397 10.38 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
11 mortality/aging MP:0010768 10.34 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
12 integument MP:0010771 10.31 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
13 neoplasm MP:0002006 10.23 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
14 muscle MP:0005369 10.22 ACTN4 BRCA1 CDKN2A EGFR ISL1 KIT
15 craniofacial MP:0005382 10.21 ACTN4 EGFR ISL1 KIT MDM2 MET
16 nervous system MP:0003631 10.21 ACTN4 BRCA1 CDKN2A EGFR HGF ISL1
17 liver/biliary system MP:0005370 10.16 ACTN4 CDKN2A EGFR ETV6 HGF KIT
18 limbs/digits/tail MP:0005371 10.13 BRCA1 CYLD EGFR ISL1 KIT MDM2
19 normal MP:0002873 10.11 BRCA1 CYLD EGFR ETV6 ISL1 KIT
20 no phenotypic analysis MP:0003012 10.1 CDKN2A EGFR ETV6 HGF ISL1 KIT
21 renal/urinary system MP:0005367 9.96 ACTN4 BRCA1 EGFR ISL1 KIT MDM2
22 pigmentation MP:0001186 9.87 BRCA1 CDKN2A EGFR HGF KIT MDM2
23 reproductive system MP:0005389 9.85 BRCA1 CDKN2A CRTC1 EGFR ISL1 KIT
24 respiratory system MP:0005388 9.61 ACTN4 BRCA1 CDKN2A CYLD EGFR KIT
25 skeleton MP:0005390 9.32 ACTN4 BRCA1 CDKN2A EGFR HGF ISL1

Drugs & Therapeutics for Salivary Gland Carcinoma

Drugs for Salivary Gland Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
3
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
4
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
5
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
6
Promethazine Approved, Investigational Phase 3 60-87-7 4927
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Fluorouracil Approved Phase 3 51-21-8 3385
10
Bevacizumab Approved, Investigational Phase 3 216974-75-3
11
Cadexomer iodine Experimental Phase 3 94820-09-4
12 Neurotransmitter Agents Phase 2, Phase 3
13 Cholinergic Agents Phase 2, Phase 3
14 Muscarinic Agonists Phase 2, Phase 3
15 Psychotropic Drugs Phase 3
16 Hypnotics and Sedatives Phase 3
17 Antidepressive Agents, Tricyclic Phase 3
18 Histamine Antagonists Phase 3
19 Antidepressive Agents Phase 3
20
Histamine Phosphate Phase 3 51-74-1 65513
21 Mitogens Phase 3
22 Antimetabolites Phase 3
23 Angiogenesis Inhibitors Phase 3
24 Immunoglobulins, Intravenous Phase 3
25 Endothelial Growth Factors Phase 3
26 Immunoglobulin G Phase 3
27
Nintedanib Approved Phase 2 656247-17-5 56843413
28
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
29
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
30
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
31
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
32
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
33
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
34
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
35
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
36
Racepinephrine Approved Phase 2 329-65-7 838
37
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
38
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
39
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
40
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
41
Testosterone Approved, Investigational Phase 2 58-22-0 6013
42
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
43
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
44 Raspberry Approved Phase 1, Phase 2
45
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
46
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
47
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
2 A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
3 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
4 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
6 Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study Unknown status NCT02558387 Phase 2 BIBF1120
7 Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors of Head and Neck, A Non-Randomized, Phase II Trial Unknown status NCT02776163 Phase 2 Cisplatin;Docetaxel
8 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
9 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
10 Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study Completed NCT01703455 Phase 2 Sorafenib
11 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Completed NCT02393820 Phase 2 pazopanib
12 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
13 Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198) Completed NCT00509002 Phase 2 Gefitinib
14 Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers Completed NCT01613768 Phase 2 eribulin mesylate
15 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
16 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
17 Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract Completed NCT02857712 Phase 2 Axitinib
18 A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas Completed NCT00045669 Phase 2 imatinib mesylate
19 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
20 Phase II Trial of Abiraterone Acetate in Patients With Relapsed and/or Metastatic, Castration Resistant Salivary Gland Cancers Completed NCT02867852 Phase 2 Abiraterone acetate
21 Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors Completed NCT00859937 Phase 2 Dasatinib
22 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
23 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
24 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
25 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
26 A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
27 A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE) Completed NCT01678105 Phase 2 Dovitinib
28 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
29 A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy Completed NCT01256385 Phase 2 Temsirolimus
30 Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract Completed NCT02860936 Phase 2 Lenvatinib
31 A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
32 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
33 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Completed NCT01175980 Phase 2 Vorinostat
34 Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients Completed NCT00458978 Phase 2 Cediranib Maleate
35 Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
36 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
37 PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES Completed NCT00002632 Phase 2 paclitaxel
38 Gemcitabine for Advanced Salivary Cancer: A Phase II Study Completed NCT00003744 Phase 2 gemcitabine
39 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
40 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
41 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
42 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
43 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
44 A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
45 A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Completed NCT01488838 Phase 2 Cisplatin: 40 mg/m2 weekly during radiation
46 Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study. Recruiting NCT03360890 Phase 2 Pembrolizumab;Docetaxel
47 A Multicenter Phase I/II Trial of A Novel MDM2 Inhibitor (APG-115) With or Without Platinum Chemotherapy in P53 Wild-Type Salivary Gland Carcinoma Recruiting NCT03781986 Phase 1, Phase 2 APG-115;Carboplatin
48 A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas Recruiting NCT04620187 Phase 2 Ado-trastuzumab (T) emtansine (T-DM1);Standard of Care Chemotherapy
49 Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111 Recruiting NCT03942653 Phase 2 Goserelin Acetate;Pembrolizumab
50 Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study. Recruiting NCT04291300 Phase 2 Lutetium-177-PSMA-I&T

Search NIH Clinical Center for Salivary Gland Carcinoma

Genetic Tests for Salivary Gland Carcinoma

Anatomical Context for Salivary Gland Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Carcinoma:

19
Salivary Gland

MalaCards organs/tissues related to Salivary Gland Carcinoma:

40
Salivary Gland, Breast, Lung, Thyroid, Bone, Skin, Lymph Node

Publications for Salivary Gland Carcinoma

Articles related to Salivary Gland Carcinoma:

(show top 50) (show all 707)
# Title Authors PMID Year
1
Autophagy and salivary gland cancer: A putative target for salivary gland tumors. 42 61
33319639 2020
2
Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: A proposal of an objective grading system. 42
33377247 2021
3
Prognostic value of the immunohistochemical expression of vascular endothelial growth factors in malignant salivary gland neoplasms: a systematic review and meta-analysis. 42
33609023 2021
4
CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. 54 61
19159612 2009
5
Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. 54 61
18355439 2008
6
Expression and cellular localization of TSC-22 in normal salivary glands and salivary gland tumors: implications for tumor cell differentiation. 54 61
18288391 2008
7
Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. 54 61
16469527 2006
8
CD151 forms a functional complex with c-Met in human salivary gland cancer cells. 61 54
16139245 2005
9
TSC-22 (TGF-beta stimulated clone-22): a novel molecular target for differentiation-inducing therapy in salivary gland cancer. 61 54
15379637 2004
10
Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. 54 61
13679209 2003
11
Cytoplasmic TSC-22 (transforming growth factor-beta-stimulated clone-22) markedly enhances the radiation sensitivity of salivary gland cancer cells. 61 54
11944908 2002
12
Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines. 54 61
11836575 2002
13
Leucine zipper structure of TSC-22 (TGF-beta stimulated clone-22) markedly inhibits the anchorage-independent growth of salivary gland cancer cells. 54 61
11836610 2002
14
In vivo enhancement of chemosensitivity of human salivary gland cancer cells by overexpression of TGF-beta stimulated clone-22. 54 61
10854535 2000
15
Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line. 61 54
10879745 2000
16
Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. 54 61
9458104 1998
17
Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. 61 54
9459148 1998
18
Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome. 61
32691231 2021
19
mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells. 61
33073679 2021
20
Incidence and survival of salivary gland cancer in children and young adults in Denmark: A nation-wide study for the period 1990-2015. 61
33550099 2021
21
Salivary Duct Carcinoma: An Aggressive Salivary Gland Carcinoma with Morphologic Variants, Newly Identified Molecular Characteristics, and Emerging Treatment Modalities. 61
33526216 2021
22
Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population. 61
33763743 2021
23
Surgical treatment of the neck in patients with salivary gland carcinoma. 61
33733522 2021
24
Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. 61
33169486 2021
25
Differential Diagnosis between Oral Metastasis of Renal Cell Carcinoma and Salivary Gland Cancer. 61
33809250 2021
26
Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers. 61
33526219 2021
27
Epithelial-Myoepithelial Carcinoma. 61
33526226 2021
28
Molecular detection of human papillomavirus-16 among Sudanese patients diagnosed with squamous cell carcinoma and salivary gland carcinoma. 61
33563329 2021
29
Prediction of Minor Salivary Gland Carcinoma: A Novel Nomogram and Risk Classification System for Overall Survival and Cancer-Specific Survival. 61
32692284 2021
30
CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition. 61
33626346 2021
31
Risk of second primary malignancy after minor salivary gland cancer: A Surveillance, Epidemiology, and End Results database analysis. 61
33590552 2021
32
Prognostic value of elective neck dissection in adenoid cystic carcinoma of head and neck: a meta-analysis. A call for randomized trials and international consensus. 61
33602647 2021
33
[Diagnosis and therapy of tumors with NTRK gene fusion]. 61
33258061 2021
34
The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. 61
33481388 2021
35
Survival of salivary gland cancer stem cells requires mTOR signaling. 61
33479203 2021
36
Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. 61
33148054 2021
37
Clinicopathological Factors are Predictors of Distant Metastases From Salivary Gland Carcinoma After Surgery Combined With 125I Internal Brachytherapy. 61
33581118 2021
38
The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay. 61
33498270 2021
39
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. 61
33467570 2021
40
Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands. 61
33247629 2021
41
Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy. 61
33718174 2021
42
The impact of nodal status in major salivary gland carcinoma: A multicenter experience and proposal of a novel N-classification. 61
33137587 2021
43
Bilateral, buccinator myomucosal advancement flaps to reconstruct central upper labial myomucosal defects after ablation of early-stage cancer in minor salivary glands. 61
32463957 2021
44
QUAD shot: an effective cyclical hypofractionated palliative radiotherapy for salivary gland carcinoma. 61
33299577 2020
45
Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group. 61
33320410 2020
46
Ambient ultraviolet radiation and major salivary gland cancer in the United States. 61
32246964 2020
47
Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - Results from a large multicenter analysis. 61
33359662 2020
48
Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. 61
32736208 2020
49
Development of sentinel lymph node biopsy technique in patients with salivary gland cancer using the IDEAL framework. 61
32576478 2020
50
Salivary gland cancer in Southern Brazil: a prognostic study of 107 cases. 61
33247564 2020

Variations for Salivary Gland Carcinoma

Cosmic variations for Salivary Gland Carcinoma:

9 (show top 50) (show all 451)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97921670 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 28
2 COSM135127924 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 28
3 COSM133255277 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.117A>C p.K39N 9:99129081-99129081 28
4 COSM97906020 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 28
5 COSM105721467 HRAS salivary gland,mouth floor,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 11:534288-534288 28
6 COSM131674386 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 21
7 COSM143041461 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 21
8 COSM84855029 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 21
9 COSM110312003 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 21
10 COSM113659175 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 21
11 COSM99562983 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 21
12 COSM99625361 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 21
13 COSM86842324 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3854C>G p.T1285S 15:43422086-43422086 21
14 COSM88223810 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 21
15 COSM93449405 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 21
16 COSM144019757 TP53 salivary gland,minor,carcinoma,NS c.742G>T p.D248Y 17:7674188-7674188 21
17 COSM106059381 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 21
18 COSM142685575 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.433G>C p.D145H 17:7675062-7675062 21
19 COSM105632589 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 21
20 COSM142828002 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.384G>C p.Q128H 17:7675111-7675111 21
21 COSM144319685 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.406C>T p.R136C 17:7675089-7675089 21
22 COSM111908814 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.483C>T p.A161= 17:7675129-7675129 21
23 COSM144039683 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.461A>T p.Q154L 17:7675118-7675118 21
24 COSM87905712 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 21
25 COSM122563517 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.173C>A p.P58H 17:7674962-7674962 21
26 COSM144178960 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.92C>A p.P31H 17:7674962-7674962 21
27 COSM143262651 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.73G>C p.D25H 17:7675062-7675062 21
28 COSM105627143 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 21
29 COSM144129656 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.184G>A p.E62K 17:7674870-7674870 21
30 COSM106065020 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 21
31 COSM144706904 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.544G>A p.E182K 17:7674870-7674870 21
32 COSM143946884 TP53 salivary gland,minor,carcinoma,NS c.*13-1G>A p.? 17:7670716-7670716 21
33 COSM144554314 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.452C>A p.P151H 17:7674962-7674962 21
34 COSM143374203 TP53 salivary gland,minor,carcinoma,NS c.*13-1G>A p.? 17:7670716-7670716 21
35 COSM144013113 TP53 salivary gland,minor,carcinoma,NS c.491G>A p.R164H 17:7675088-7675088 21
36 COSM93183307 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 21
37 COSM93239617 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 21
38 COSM144109523 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.17A>T p.Q6L 17:7675118-7675118 21
39 COSM111765171 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 21
40 COSM112283179 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 21
41 COSM142842148 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 21
42 COSM88218639 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 21
43 COSM144182805 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.24G>C p.Q8H 17:7675111-7675111 21
44 COSM142858982 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 21
45 COSM145021213 TP53 salivary gland,minor,carcinoma,NS c.877-1G>A p.? 17:7670716-7670716 21
46 COSM144082461 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.6C>T p.A2= 17:7675129-7675129 21
47 COSM143166669 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.46C>T p.R16C 17:7675089-7675089 21
48 COSM144943249 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.452C>A p.P151H 17:7674962-7674962 21
49 COSM144091358 TP53 salivary gland,minor,carcinoma,NS c.298G>T p.D100Y 17:7674188-7674188 21
50 COSM142563012 TP53 salivary gland,minor,carcinoma,NS c.877-1G>A p.? 17:7670716-7670716 21

Expression for Salivary Gland Carcinoma

Search GEO for disease gene expression data for Salivary Gland Carcinoma.

Pathways for Salivary Gland Carcinoma

Pathways related to Salivary Gland Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 SOX2 MET MDM2 KIT HGF EGFR
2
Show member pathways
12.7 MET MDM2 MAML2 KIT HGF EGFR
3 12.66 MET MDM2 KIT HGF EGFR CDKN2A
4
Show member pathways
12.57 MET MDM2 KIT HGF EGFR
5
Show member pathways
12.55 MET KIT HGF EGFR CDKN2A BRCA1
6
Show member pathways
12.34 MET MDM2 HGF EGFR CDKN2A BRCA1
7 12.28 SPHK1 MET HGF EGFR
8 12.16 MET MDM2 HGF EGFR
9 12.12 TP63 MET MDM2 EGFR CDKN2A BRCA1
10
Show member pathways
11.76 MET HGF EGFR
11 11.75 MDM2 EGFR BRCA1
12 11.62 MDM2 CDKN2A BRCA1
13 11.62 MDM2 EGFR CDKN2A
14 11.59 MET EGFR ACTN4
15 11.58 MET KIT EGFR
16 11.48 TP63 SOX2 MET ISL1 HGF
17 11.42 SOX2 KIT ISL1
18 11.29 MET HGF EGFR
19 11.23 MET HGF EGFR
20 11.18 MET HGF EGFR
21 11.14 TP63 MET MDM2 HGF EGFR
22 11.09 MET HGF EGFR
23
Show member pathways
10.89 TP63 MDM2 CDKN2A
24
Show member pathways
10.65 MET HGF

GO Terms for Salivary Gland Carcinoma

Cellular components related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 TSC22D1 TP63 SPHK1 SOX2 SERPINA3 MDM2
2 protein-containing complex GO:0032991 9.63 TP63 MDM2 EGFR CDKN2A BRCA1 ACTN4
3 platelet alpha granule lumen GO:0031093 9.43 SERPINA3 HGF ACTN4
4 nuclear body GO:0016604 9.02 MDM2 CRTC1 CDKN2A BRCA1 ACTN4

Biological processes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.06 TSC22D1 TP63 MDM2 KIT ISL1 ETV6
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP63 SOX2 EGFR CDKN2A BRCA1 ACTN4
3 liver development GO:0001889 9.75 MET HGF EGFR
4 positive regulation of protein kinase B signaling GO:0051897 9.71 MET KIT HGF EGFR
5 positive regulation of kinase activity GO:0033674 9.7 MET KIT EGFR
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.67 SPHK1 EGFR ACTN4
7 cellular response to growth factor stimulus GO:0071363 9.65 SPHK1 MDM2 EGFR
8 positive regulation of angiogenesis GO:0045766 9.62 SPHK1 ISL1 HGF BRCA1
9 epithelial cell proliferation GO:0050673 9.58 KIT HGF
10 amyloid fibril formation GO:1990000 9.57 MDM2 CDKN2A
11 hepatocyte growth factor receptor signaling pathway GO:0048012 9.56 MET HGF
12 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.55 TP63 SOX2
13 positive regulation of cell migration GO:0030335 9.55 SPHK1 KIT HGF EGFR ACTN4
14 tongue development GO:0043586 9.54 KIT EGFR
15 positive regulation of Notch signaling pathway GO:0045747 9.54 TP63 MAML2 KIT
16 somatic stem cell division GO:0048103 9.51 KIT CDKN2A
17 positive regulation of transcription by RNA polymerase II GO:0045944 9.4 TP63 SOX2 MET MDM2 MAML2 ISL1
18 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.26 MET HGF
19 negative regulation of intracellular estrogen receptor signaling pathway GO:0033147 9.13 TP63 ISL1 BRCA1

Molecular functions related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.65 TP63 SOX2 MDM2 ISL1 ETV6
2 DNA binding GO:0003677 9.61 TP63 SPHK1 SOX2 SERPINA3 ISL1 H2AC18
3 5S rRNA binding GO:0008097 9.37 TST MDM2
4 p53 binding GO:0002039 9.33 TP63 MDM2 CDKN2A
5 MDM2/MDM4 family protein binding GO:0097371 9.32 TP63 CDKN2A
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 MET KIT EGFR

Sources for Salivary Gland Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....